Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cobicistat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 known ✓ | P08684 | 20/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cobicistat SCHEMBL10201695 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| Cobicistat SCHEMBL10201697 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| Cobicistat SCHEMBL16632480 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| Cobicistat SCHEMBL2736227 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL18159507 | 0.98 | CYP3A4 (0.95) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL20674820 | 0.97 | CYP3A4 (0.94) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL23678770 | 0.97 | CYP3A4 (0.94) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL18583448 | 0.96 | CYP3A4 (0.93) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL15318473 | 0.95 | CYP3A4 (0.91) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL10129122 | 0.95 | CYP3A4 (0.91) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351556-B2 | Process for the preparation of 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2s)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4YL] methyl} carbamoyl) amino]-4-(morpholin-4-yl)butanoyl]amino)-1,6-diphenylhexan-2-yl]carbamate | MSN LABORATORIES PRIVATE LIMITED (IN) | 2019-07-16 | — | — | US | claimed |
| US-20180030043-A1 | NOVEL PROCESS FOR THE PREPARATION OF 1,3-THIAZOL-5-YLMETHYL [(2R,5R)-5- CARBAMOYL) AMINO] -4-(MORPHOLIN-4-YL)BUTANOYL]AMINO}-1,6-DIPHENYLHEXAN-2-YL]CARBAMATE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-02-01 | — | — | US | claimed |
| US-20240041764-A1 | Sustained-Release Oral Fosamprenavir Formulation for Treatment of Reflux | N-ZYME BIOMEDICAL INC. (CA) | 2024-02-08 | — | — | US | disclosed |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | EWHA WOMANS UNIVERSITY (KR) | 2023-07-13 | — | — | US | disclosed |
| US-11185548-B2 | Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases | HELMHOLTZ ZENTRUM MUNCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2021-11-30 | — | — | US | disclosed |
| EP-3661937-B1 | CRYSTALLINE FORMS OF ETHYL ((S)-((((2R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-4-FLUORO-2,5-DIHYDROFURAN-2-YL)OXY)METHYL)(PHENOXY)PHOSPHORYL)-L-ALANINATE (GS-9131) FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-10851125-B2 | Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate | GILEAD SCIENCES, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3696171-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3689353-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3112355-B1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES INC (US) | 2020-04-29 | — | — | EP | disclosed |
| US-10351556-B2 | Process for the preparation of 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2s)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4YL] methyl} carbamoyl) amino]-4-(morpholin-4-yl)butanoyl]amino)-1,6-diphenylhexan-2-yl]carbamate | MSN LABORATORIES PRIVATE LIMITED (IN) | 2019-07-16 | — | — | US | disclosed |
| US-20090291952-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES,INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES,INC. (US) | 2009-07-16 | — | — | US | disclosed |
| WO-2008103949-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080207620-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207620-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
| WO-2008010921-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | PNP, UNG, PNPO | CYP3A4 11/4885CYP2D6 50/4885CYP2C9 113/4885 |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | SLC10A1, SLC10A2, SLC26A4 | CYP3A4 149/4885CYP2D6 92/4885CYP2C9 410/4885 |
| US-20080207620-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CYP3A4 160/4885CYP2D6 105/4885CYP2C9 476/4885 |
| US-10351556-B2 | Process for the preparation of 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2s)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4YL] methyl} carbamoyl) amino]-4-(morpholin-4-yl)butanoyl]amino)-1,6-diphenylhexan-2-yl]carbamate | METTL3, CPS1, PKD1 | CYP3A4 810/4885CYP2D6 899/4885CYP2C9 700/4885 |
| US-11185548-B2 | Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases | CYP7A1, CYP7B1, CYP27A1 | CYP3A4 45/4885CYP2D6 64/4885CYP2C9 88/4885 |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | ACE2, ACE, TMPRSS2 | CYP3A4 3014/4885CYP2D6 4582/4885CYP2C9 3710/4885 |
| US-20090291952-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CYP3A4 415/4885CYP2D6 140/4885CYP2C9 615/4885 |
| US-20180030043-A1 | NOVEL PROCESS FOR THE PREPARATION OF 1,3-THIAZOL-5-YLMETHYL [(2R,5R)-5- CARBAMOYL) AMINO] -4-(MORPHOLIN-4-YL)BUTANOYL]AMINO}-1,6-DIPHENYLHEXAN-2-YL]CARBAMATE | CPS1, METTL3, ACMSD | CYP3A4 633/4885CYP2D6 871/4885CYP2C9 747/4885 |
| US-10851125-B2 | Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate | MTAP, PNP, TYMP | CYP3A4 1451/4885CYP2D6 2036/4885CYP2C9 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.